Bailard’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.9M | Buy |
37,862
+3,887
| +11% | +$1.81M | 0.39% | 60 |
|
|
2025
Q4 | $15.4M | Sell |
33,975
-664
| -2% | -$286K | 0.34% | 65 |
|
|
2025
Q3 | $13.6M | Sell |
34,639
-3,508
| -9% | -$1.47M | 0.29% | 70 |
|
|
2025
Q2 | $17M | Buy |
38,147
+200
| +0.5% | +$92.2K | 0.4% | 59 |
|
|
2025
Q1 | $18.4M | Buy |
37,947
+532
| +1% | +$248K | 0.47% | 51 |
|
|
2024
Q4 | $15.1M | Sell |
37,415
-1,102
| -3% | -$511K | 0.39% | 62 |
|
|
2024
Q3 | $17.9M | Buy |
38,517
+37
| +0.1% | +$17.8K | 0.47% | 51 |
|
|
2024
Q2 | $18M | Sell |
38,480
-260
| -0.7% | -$113K | 0.5% | 48 |
|
|
2024
Q1 | $16.2M | Buy |
38,740
+410
| +1% | +$173K | 0.45% | 51 |
|
|
2023
Q4 | $15.6M | Buy |
38,330
+908
| +2% | +$335K | 0.46% | 46 |
|
|
2023
Q3 | $13M | Buy |
37,422
+1,047
| +3% | +$366K | 0.43% | 50 |
|
|
2023
Q2 | $12.8M | Buy |
36,375
+372
| +1% | +$125K | 0.45% | 48 |
|
|
2023
Q1 | $11.3M | Buy |
36,003
+23,165
| +180% | +$6.95M | 0.41% | 55 |
|
|
2022
Q4 | $3.71M | Buy |
12,838
+10,201
| +387% | +$3.11M | 0.14% | 129 |
|
|
2022
Q3 | $764K | Buy |
+2,637
| New | +$759K | 0.03% | 273 |
|
|
2021
Q2 | – | Sell |
-1,591
| Closed | -$342K | – | 765 |
|
|
2021
Q1 | $342K | Sell |
1,591
-600
| -27% | -$132K | 0.01% | 473 |
|
|
2020
Q4 | $518K | Buy |
2,191
+59
| +3% | +$13.5K | 0.02% | 324 |
|
|
2020
Q3 | $580K | Sell |
2,132
-70
| -3% | -$19.3K | 0.03% | 264 |
|
|
2020
Q2 | $639K | Hold |
2,202
| – | – | 0.04% | 238 |
|
|
2020
Q1 | $524K | Buy |
2,202
+2
| +0.1% | +$459 | 0.04% | 222 |
|
|
2019
Q4 | $482K | Hold |
2,200
| – | – | 0.03% | 294 |
|
|
2019
Q3 | $373K | Hold |
2,200
| – | – | 0.02% | 351 |
|
|
2019
Q2 | $403K | Hold |
2,200
| – | – | 0.02% | 338 |
|
|
2019
Q1 | $405K | Hold |
2,200
| – | – | 0.03% | 352 |
|
|
2018
Q4 | $365K | Hold |
2,200
| – | – | 0.02% | 379 |
|
|
2018
Q3 | $424K | Hold |
2,200
| – | – | 0.02% | 413 |
|
|
2018
Q2 | $374K | Hold |
2,200
| – | – | 0.02% | 420 |
|
|
2018
Q1 | $359K | Hold |
2,200
| – | – | 0.02% | 391 |
|
|
2017
Q4 | $330K | Buy |
+2,200
| New | +$326K | 0.02% | 361 |
|
|
2016
Q1 | – | Sell |
-3,500
| Closed | -$440K | – | 355 |
|
|
2015
Q4 | $440K | Buy |
+3,500
| New | +$423K | 0.19% | 146 |
|
Other funds holding VRTX
VCM
VPM
Bailard's VRTX Position: Q1 2026 in Review
Bailard increased its Vertex Pharmaceuticals (VRTX) stake by 11% in Q1 2026, buying an estimated $1.81M and bringing the position to 37,862 shares worth $16.9M. The position accounts for 0.39% of the portfolio, ranked #60.
Bailard first reported a position in VRTX in Q4 2015 and has held it in 30 quarters since. The position peaked at $18.4M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Bailard held 37,862 shares of Vertex Pharmaceuticals worth $16.9M as of Q1 2026.
- Bailard bought 3,887 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.81M.
- Vertex Pharmaceuticals made up 0.39% of Bailard's portfolio in Q1 2026, its #60 holding.
- Bailard first reported a position in Vertex Pharmaceuticals in Q4 2015 and has held it in 30 quarters since.
- Bailard's Vertex Pharmaceuticals position peaked at $18.4M in Q1 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.